Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab.

Gillies, M. C., A. Campain, R. Walton, J. M. Simpson, J. J. Arnold, R. H. Guymer, I. L. McAllister, A. P. Hunyor, R. W. Essex, N. Morlet, D. Barthelmes and G. Fight Retinal Blindness Study (2015). “Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab.” Ophthalmology 122(3): 589-594 e581. IF = 6.1